title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Roche provides update on Alzheimer's Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer's disease,20220616T050000,https://www.globenewswire.com/news-release/2022/06/16/2463591/0/en/Roche-provides-update-on-Alzheimer-s-Prevention-Initiative-study-evaluating-crenezumab-in-autosomal-dominant-Alzheimer-s-disease.html,CHGCF,0.022322,Neutral,0.018638
"Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash",20241209T213000,https://www.globenewswire.com/news-release/2024/12/09/2994099/0/en/Roche-commences-tender-offer-for-all-shares-of-Poseida-Therapeutics-Inc-for-9-00-per-share-in-cash-plus-a-non-tradeable-contingent-value-right-for-up-to-4-00-per-share-in-cash.html,CHGCF,0.030026,Neutral,0.110404
"Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies",20241126T061000,https://www.globenewswire.com/news-release/2024/11/26/2987189/0/en/Roche-enters-into-a-definitive-agreement-to-acquire-Poseida-Therapeutics-including-cell-therapy-candidates-and-related-platform-technologies.html,CHGCF,0.017145,Neutral,0.102558
